Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595035 | 1.00 | HTT (0.58) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL30732407 | 0.94 | HTT (0.54) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL31058797 | 0.92 | HTT (0.55) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL21427814 | 0.92 | HTT (0.55) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL31058801 | 0.92 | HTT (0.55) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL31058794 | 0.92 | HTT (0.55) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL23120082 | 0.91 | HTT (0.51) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL29595147 | 0.91 | HTT (0.51) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL8508295 | 0.91 | HTT (0.51) | HTTMAPK1HRH1TP53HRH3 | |
| SCHEMBL28723685 | 0.91 | HTT (0.51) | HTTMAPK1HRH1TP53HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3775325-B1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2024-08-28 | — | — | EP | claimed |
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | BASF SE (DE) | 2024-08-06 | — | — | US | claimed |
| CN-111918985-B | Composition for tin-silver alloy electroplating comprising complexing agent | 巴斯夫欧洲公司 | 2024-02-02 | — | — | CN | claimed |
| US-20210025070-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-01-28 | — | — | US | claimed |
| EP-1356296-A2 | RAPID AND SENSITIVE DETECTION OF PROTEIN AGGREGATION | Minerva Biotechnologies Corporation (US) | 2003-10-29 | — | — | EP | claimed |
| WO-2000043791-A9 | RAPID AND SENSITIVE DETECTION OF ABERRANT PROTEIN AGGREGATION IN NEURODEGENERATIVE DISEASES | MINERVA BIOTECHNOLOGIES CORP (US) | 2002-03-28 | — | — | WO | claimed |
| EP-1169646-A2 | RAPID AND SENSITIVE DETECTION OF ABERRANT PROTEIN AGGREGATION IN NEURODEGENERATIVE DISEASES | Minerva Biotechnologies Corporation (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2002001230-A2 | RAPID AND SENSITIVE DETECTION OF PROTEIN AGGREGATION | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2002-01-03 | — | — | WO | claimed |
| WO-2000043791-A2 | RAPID AND SENSITIVE DETECTION OF ABERRANT PROTEIN AGGREGATION IN NEURODEGENERATIVE DISEASES | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2000-07-27 | — | — | WO | claimed |
| US-12559852-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | BASF SE (DE) | 2026-02-24 | — | — | US | disclosed |
| EP-3775325-B1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2024-08-28 | — | — | EP | disclosed |
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | BASF SE (DE) | 2024-08-06 | — | — | US | disclosed |
| US-20240060201-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2024-02-22 | — | — | US | disclosed |
| CN-111918985-B | Composition for tin-silver alloy electroplating comprising complexing agent | 巴斯夫欧洲公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-1991018034-A1 | ADVANCED AND UNADVANCED COMPOSITIONS, NUCLEOPHILIC DERIVATIVES THEREOF AND CURABLE AND COATING COMPOSITIONS THEREOF | THE DOW CHEMICAL COMPANY (US) | 1991-11-28 | — | — | WO | disclosed |
| US-5021471-A | Polyepoxides and epoxy resins modified by a pyridine compound and acid; solvent- and water-systems; coatings, molding materials and castings; chemical resistance; flexibility | THE DOW CHEMICAL COMPANY (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0176630-B1 | LIQUID DEVELOPER FOR DEVELOPMENT OF ELECTROSTATIC IMAGES | AGFA-GEVAERT N.V. (BE) | 1988-05-04 | — | — | EP | disclosed |
| US-4639404-A | ANIONIC POLYMERS NEUTRALIZED WITH METAL COORDINATION CATIONS | AGFA-GEVAERT, N.V. (BE) | 1987-01-27 | — | — | US | disclosed |
| EP-0176630-A1 | Liquid developer for development of electrostatic images | AGFA-GEVAERT N.V. (BE) | 1986-04-09 | — | — | EP | disclosed |
| US-3965069-A | Polyphenylene oxide is prepared using a mixture of manganese chelates as a catalyst | GENERAL ELECTRIC COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559852-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | SLC13A3, GNA11, AP3D1 | HTT 1373/4885MAPK1 1472/4885HRH1 1703/4885 |
| US-20240060201-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | SLC39A11, SCN11A, S100A11 | HTT 785/4885MAPK1 2445/4885HRH1 2239/4885 |
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | SCN11A, GRIA3, NR3C1 | HTT 2093/4885MAPK1 1998/4885HRH1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.